Latest news
ARWR Rallies 7% This Week As Europe Edges Closer To Redemplo Approval Amid Analyst Optimism - StocktwitsStocktwits · Fri, 07 Aug 2026 05:18:39 GMTArrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target - TipRanksTipRanks · Wed, 05 Aug 2026 15:37:00 GMTARWR: Positive SHTG phase III data and REDEMPLO launch momentum drive revenue and pipeline progress - TradingViewTradingView · Tue, 04 Aug 2026 22:58:39 GMTARWR: Positive SHTG data, accelerating REDEMPLO launch, and robust pipeline drive growth outlook - TradingViewTradingView · Tue, 04 Aug 2026 22:18:53 GMTArrowhead Pharmaceuticals Q3 Earnings Call Highlights - TradingViewTradingView · Tue, 04 Aug 2026 22:03:56 GMTArrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Arrowhead Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc. · Tue, 04 Aug 2026 21:11:19 GMTARWR: Revenue up, net loss widened; REDEMPLO and pipeline achieved major clinical and commercial milestones - TradingViewTradingView · Tue, 04 Aug 2026 20:11:01 GMTArrowhead Pharmaceuticals Q3 revenue jumps on REDEMPLO growth - TradingViewTradingView · Tue, 04 Aug 2026 20:10:54 GMT